Neurocrine Biosciences
Scientific leader in advanced analytical technologies for CMC development, serving as the analytical lead across multiple projects and sub-teams for small molecule and peptide drug candidates. Drives analytical strategy and execution to support process and formulation development, clinical manufacturing, regulatory submissions, and commercialization. Provides mentorship to junior staff and represents analytical activities with cross-functional teams and external CDMOs while ensuring cGMP and regulatory compliance.
Headquarters
San Diego, California, United States
Company Size
1001-5000 employees
Founded
1992
Neurocrine Biosciences is a biopharmaceutical company focused on discovering and developing treatments for patients with neurological, psychiatric, endocrine, and immunological disorders. With over 30 years of research, the company works to bring hope to people living with rare diseases and conditions that lack viable treatment options. Neurocrine develops and markets approved medicines while maintaining an active clinical pipeline across multiple therapeutic areas.
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
1 day ago
Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX
5 hours ago
Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback
23 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Neurocrine Biosciences.
Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX
7 hours ago